Chemotherapy-induced Peripheral Neuropathy Clinical Trial
Official title:
Evaluating the Efficacy of Photobiomodulation Therapy in the Management of Chemotherapy-induced Peripheral Neuropathy: a Pilot Trial
This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is that PBM can reduce the severity of CIPN in cancer patients, increasing the patient's quality of life.
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the common complications of cancer treatment and involves paresthesia, numbness and/or burning pain in distal limbs. This condition has a high health impact because it is associated with psychological distress, fall risk, and poor sleep quality. Furthermore, it impairs patients' daily activities and thereby decreases their quality of life. The overall incidence of CIPN is approximately 68% in the first month after chemotherapy. The available evidence for preventive and therapeutic options for CIPN is limited. Therefore, only symptom management based on pharmacological and/or physical therapy is applied with limited success. Our research group showed that photobiomodulation (PBM) has the potential to reduce the development of CIPN in breast cancer patients (unpublished data). PBM uses visible and/or (near)-infrared light at a low power produced by laser diodes or light-emitting diodes (LED) to stimulate tissue repair and reduce inflammation and (neuropathic) pain. The aim of this project is to evaluate the effectiveness of PBM in the management of CIPN in general. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05528263 -
Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)
|
N/A | |
| Completed |
NCT03272919 -
Chemotherapy Induced Peripheral Neuropathy (CIPN)
|
N/A | |
| Not yet recruiting |
NCT05840562 -
Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy
|
Phase 3 | |
| Completed |
NCT02553863 -
The Effectiveness and Cost-effectiveness of Acupuncture in Managing Chemotherapy-induced Peripheral Neuropathy
|
N/A | |
| Recruiting |
NCT04786977 -
Physiologic Measure of VIPN
|
||
| Completed |
NCT03655587 -
Impact of an Orthotic Intervention in Children With Peripheral Neuropathy
|
N/A | |
| Completed |
NCT03687970 -
A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)
|
N/A | |
| Terminated |
NCT04770402 -
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
|
N/A | |
| Completed |
NCT03254394 -
Lidocaine for Oxaliplatin-induced Neuropathy
|
Phase 1/Phase 2 | |
| Completed |
NCT04367480 -
Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral Neuropathy
|
N/A | |
| Recruiting |
NCT04237194 -
A New Diagnostic Method to Assess Paclitaxel-Induced Peripheral Neuropathy
|
||
| Completed |
NCT04843410 -
Effect of Exercise in the Management of Peripheral Neuropathy
|
N/A | |
| Terminated |
NCT03782402 -
Cannabinoids for Taxane Induced Peripheral Neuropathy
|
Phase 2 | |
| Recruiting |
NCT05121558 -
The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)
|
Phase 3 | |
| Withdrawn |
NCT04492436 -
A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo
|
Phase 2 | |
| Not yet recruiting |
NCT03112057 -
Visualize Nociceptor Changes in Neuropathic Human
|
N/A | |
| Completed |
NCT04262778 -
Diagnostic of Chemotherapy Induced Neuropathy in Children
|
||
| Recruiting |
NCT06324344 -
Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy Induced Peripheral Neuropathy (CIPN)
|
N/A | |
| Recruiting |
NCT05368428 -
Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer
|
N/A | |
| Recruiting |
NCT05291286 -
BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients
|
Early Phase 1 |